Should Cancer Trial Eligibility Become More Inclusive?

The article discusses the findings of a new analysis revealing that patients with treatment-refractory cancers who received eligibility waivers for a pan-cancer clinical trial had similar outcomes to those who met the original criteria. Topics include: the benefits of broadening eligibility criteria in clinical trials, the real-world applicability of trial results, and the ongoing debate about the impact of increased trial inclusivity on treatment safety and efficacy.